Its characterization is limited to molecular-level investigation conducted exclusively within controlled laboratory research environments
Ideal candidates are typically over 40 and dissatisfied with their inability to lose weight, decreased sexual function, or a decline in energy level and cognitive function
GLP-1 Market Share, By Drug Class, 2025 (%) The triple agonists (Pipeline) segment held a 3% share of the market in 2025 and is expected to grow at the fastest CAGR of 29.4% during the projection period
Unlike older weight loss medications, tirzepatide's dual-pathway action produces stronger appetite suppression and metabolic changes in most patients
In the pancreas, GLP-1RAs enhance insulin secretion and inhibit the release of glucagon, a hormone that induces the breakdown of stored sugars into the bloodstream
The body set point is a theory suggesting your brain and body, particularly the hypothalamus, maintain a specific, natural weight range through regulating metabolism, hormones, and hunger, often resisting weight loss
